Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Rajabally, Yusuf
  • Scotton, Sangeeta
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Baars, Adája Elisabeth|||0000-0001-7842-0871
  • Cortese, Andrea
  • Vegezzi, Elisa|||0000-0001-8776-6831
  • Höftberger, Romana|||0000-0002-5769-1100
  • Zimprich, Fritz|||0000-0002-6998-5480
  • Roesler, Cornelia
  • Nobile-Orazio, Eduardo|||0000-0003-2624-8138
  • Liberatore, Giuseppe|||0000-0003-2666-1678
  • Hiew, Fu Liong|||0000-0002-4708-3734
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Carvajal, Alejandra
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Usón-Martín, Mercedes
  • Albertí, Olalla
  • López Pérez, María Ángeles
  • Márquez, Fabian
  • Pardo-Fernández, Julio
  • Muñoz-Delgado, Laura|||0000-0002-8818-1824
  • Cabrera-Serrano, Macarena|||0000-0003-3109-6095
  • Ortiz-Castellon, Nicolau|||0000-0001-9544-2642
  • Bartolomé, Manuel
  • Duman, Özgür
  • Bril, Vera
  • Segura-Chávez, Darwin
  • Pitarokoili, Kalliopi
  • Steen, Claudia
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN).MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up.ResultsForty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients.DiscussionAnti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases.Classification of EvidenceThis study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab.